Drugs / Kratom
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04392011 | Oct 2019 → Aug 2021 | — | Washington State University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07218549 | Sep 2026 → Dec 2028 expected | substance-related disorder | Christopher D. Verrico | Recruiting | No outcome recorded |
| Phase 1 | NCT06072170 | Aug 2023 → Jan 2024 | — | Altasciences Company Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kratom | “Kratom (Mitragyna speciosa) is a tree native to Southeast Asia that produces constituents with opioid-like effects.” NCT04392011 ↗ |
| Known as | Mitragyna speciosa | “Kratom (Mitragyna speciosa) is a tree native to Southeast Asia that produces constituents with opioid-like effects.” NCT04392011 ↗ |
| Action | Inhibit | “these two constituents and extracts made from commercially available kratom products are strong inhibitors of the drug metabolizing enzymes cytochrome P450 (CYP) 2D6 and CYP3A4.” NCT04392011 ↗ |
| Route | Oral | “by mouth as a tea” NCT04392011 ↗ |